US20180325901A1 - Chiral diaryl macrocycles and uses thereof - Google Patents
Chiral diaryl macrocycles and uses thereof Download PDFInfo
- Publication number
- US20180325901A1 US20180325901A1 US15/745,915 US201615745915A US2018325901A1 US 20180325901 A1 US20180325901 A1 US 20180325901A1 US 201615745915 A US201615745915 A US 201615745915A US 2018325901 A1 US2018325901 A1 US 2018325901A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- alk
- fusion protein
- cancer
- ros1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1Cc2ccc3ccc(c3c2)C(=O)N([6*])C([3*])C([2*])CC2=C1C([5*])=C([4*])C=C2 Chemical compound [1*]C1Cc2ccc3ccc(c3c2)C(=O)N([6*])C([3*])C([2*])CC2=C1C([5*])=C([4*])C=C2 0.000 description 12
- LPLZJOKOUUKSOP-UMTGBFJISA-M *.*.*.*.*.CC(C)(C)[S@@](=O)/N=C/C1=CC(F)=CC=C1O.CC(C)(C)[SH]=O.CCO/C=C/C(=O)OCC.CCOC(=O)C1=C(N)NN=C1.CCOC(=O)C1=C2CC(=O)C=CN2N=C1.CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1.CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1.C[C@@H](N)C1=C(O)C=CC(F)=C1.C[C@@H](N)C1=CC(F)=CC=C1O.C[C@@H](N[S@](=O)C(C)(C)C)C1=CC(F)=CC=C1O.C[Mg]Br.N.O=CC1=CC(F)=CC=C1O.O=P(Cl)(Cl)Cl Chemical compound *.*.*.*.*.CC(C)(C)[S@@](=O)/N=C/C1=CC(F)=CC=C1O.CC(C)(C)[SH]=O.CCO/C=C/C(=O)OCC.CCOC(=O)C1=C(N)NN=C1.CCOC(=O)C1=C2CC(=O)C=CN2N=C1.CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1.CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1.C[C@@H](N)C1=C(O)C=CC(F)=C1.C[C@@H](N)C1=CC(F)=CC=C1O.C[C@@H](N[S@](=O)C(C)(C)C)C1=CC(F)=CC=C1O.C[Mg]Br.N.O=CC1=CC(F)=CC=C1O.O=P(Cl)(Cl)Cl LPLZJOKOUUKSOP-UMTGBFJISA-M 0.000 description 1
- QTAFJBIUWSMACG-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C1=CC2=C(C=C1)OCCO2.C1=CCCC1.C1=CCCC1.C1=CNCCC1.C1=CSC=CN1.C1=NCCC1.C1=NCCO1.C1CC1.C1CC2CCC1CC2.C1CC2CCC1O2.C1CCCC1.C1CCCCCC1.C1CCCNCC1.C1CCCOCC1.C1CCN2CCCCC2C1.C1CCNCC1.C1CCNCC1.C1CCOC1.C1CCSC1.C1CNC1.C1CNNC1.C1COC1.C1COCCN1.C1CSCCN1.C=C1CCCCCC1.C=C1CCCCNC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCCN1.O=C1CCCN1.O=C1CCCNC1.O=C1CCCO1.O=C1CCCO1.O=S1(=O)CCCC1.O=S1(=O)CCCCCC1.O=S1(=O)CCNCC1 Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C1=CC2=C(C=C1)OCCO2.C1=CCCC1.C1=CCCC1.C1=CNCCC1.C1=CSC=CN1.C1=NCCC1.C1=NCCO1.C1CC1.C1CC2CCC1CC2.C1CC2CCC1O2.C1CCCC1.C1CCCCCC1.C1CCCNCC1.C1CCCOCC1.C1CCN2CCCCC2C1.C1CCNCC1.C1CCNCC1.C1CCOC1.C1CCSC1.C1CNC1.C1CNNC1.C1COC1.C1COCCN1.C1CSCCN1.C=C1CCCCCC1.C=C1CCCCNC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCCN1.O=C1CCCN1.O=C1CCCNC1.O=C1CCCO1.O=C1CCCO1.O=S1(=O)CCCC1.O=S1(=O)CCCCCC1.O=S1(=O)CCNCC1 QTAFJBIUWSMACG-UHFFFAOYSA-N 0.000 description 1
- RCMOLTWGZLQONW-UHFFFAOYSA-N C1=CC2=C(C=CS2)S1.C1=CC=C2C=CC=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CC=NC2=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2NC=CC2=C1.C1=CC=C2OC=CC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=C2SC=NC2=C1.C1=CC=C2SC=NC2=C1.C1=CC=NC=C1.C1=CCN=C1.C1=CN=C2C=CC=NC2=C1.C1=CN=C2CC=CC2=C1.C1=CN=C2N=CC=CC2=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CSC=C1.C1=CSC=N1.C1=CSN=C1.C1=NC=NC=N1.C1=NCN=N1 Chemical compound C1=CC2=C(C=CS2)S1.C1=CC=C2C=CC=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CC=NC2=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2NC=CC2=C1.C1=CC=C2OC=CC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=C2SC=NC2=C1.C1=CC=C2SC=NC2=C1.C1=CC=NC=C1.C1=CCN=C1.C1=CN=C2C=CC=NC2=C1.C1=CN=C2CC=CC2=C1.C1=CN=C2N=CC=CC2=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CSC=C1.C1=CSC=N1.C1=CSN=C1.C1=NC=NC=N1.C1=NCN=N1 RCMOLTWGZLQONW-UHFFFAOYSA-N 0.000 description 1
- WXMRBFSPVWIKAR-UHFFFAOYSA-N C1=CC2CCC1C2.C1=CC2CCCCC2C1.C1=CCC=CC1.C1=CCCC1.C1=CCCC=C1.C1=CCCCC1.C1CC1.C1CC2CC(C1)C2.C1CC2CC12.C1CC2CC2C1.C1CC2CCC1C2.C1CC2CCC1CC2.C1CC2CCCC2C1.C1CCC1.C1CCC2CCCC2C1.C1CCC2CCCCC2C1.C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCCCCCC1 Chemical compound C1=CC2CCC1C2.C1=CC2CCCCC2C1.C1=CCC=CC1.C1=CCCC1.C1=CCCC=C1.C1=CCCCC1.C1CC1.C1CC2CC(C1)C2.C1CC2CC12.C1CC2CC2C1.C1CC2CCC1C2.C1CC2CCC1CC2.C1CC2CCCC2C1.C1CCC1.C1CCC2CCCC2C1.C1CCC2CCCCC2C1.C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCCCCCC1 WXMRBFSPVWIKAR-UHFFFAOYSA-N 0.000 description 1
- BHFZOLHPNIOMCY-XKRLPEANSA-M CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O)C=CC(F)=C3)C=CN2N=C1.CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O[C@@H](C)CCC(=O)OC(C)(C)C)C=CC(F)=C3)C=CN2N=C1.CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O[C@@H](C)CNC(=O)OC(C)(C)C)C=CC(F)=C3)C=CN2N=C1.C[C@@H](CN)OC1=C([C@@H](C)NC2=NC3=C(C(=O)O)C=NN3C=C2)C=C(F)C=C1.C[C@@H](O)CCC(=O)OC(C)(C)C.C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@H](C)C2=C(C=CC(F)=C2)O1.[Li]O Chemical compound CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O)C=CC(F)=C3)C=CN2N=C1.CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O[C@@H](C)CCC(=O)OC(C)(C)C)C=CC(F)=C3)C=CN2N=C1.CCOC(=O)C1=C2N=C(N[C@H](C)C3=C(O[C@@H](C)CNC(=O)OC(C)(C)C)C=CC(F)=C3)C=CN2N=C1.C[C@@H](CN)OC1=C([C@@H](C)NC2=NC3=C(C(=O)O)C=NN3C=C2)C=C(F)C=C1.C[C@@H](O)CCC(=O)OC(C)(C)C.C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@H](C)C2=C(C=CC(F)=C2)O1.[Li]O BHFZOLHPNIOMCY-XKRLPEANSA-M 0.000 description 1
- FIKPXCOQUIZNHB-WDEREUQCSA-N C[C@H]1CNC(=O)C2=C3\N=C(C=CN3\N=C/2)N[C@H](C)C2=C(C=CC(F)=C2)O1 Chemical compound C[C@H]1CNC(=O)C2=C3\N=C(C=CN3\N=C/2)N[C@H](C)C2=C(C=CC(F)=C2)O1 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/745,915 US20180325901A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195081P | 2015-07-21 | 2015-07-21 | |
US201662302231P | 2016-03-02 | 2016-03-02 | |
US15/745,915 US20180325901A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
PCT/US2016/043132 WO2017015367A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/043132 A-371-Of-International WO2017015367A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/998,763 Continuation US11452725B2 (en) | 2015-07-21 | 2020-08-20 | Chiral diaryl macrocycles and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180325901A1 true US20180325901A1 (en) | 2018-11-15 |
Family
ID=57834656
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/745,915 Abandoned US20180325901A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
US16/998,763 Active 2036-07-24 US11452725B2 (en) | 2015-07-21 | 2020-08-20 | Chiral diaryl macrocycles and uses thereof |
US17/819,858 Pending US20230346786A1 (en) | 2015-07-21 | 2022-08-15 | Chiral diaryl macrocycles and uses thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/998,763 Active 2036-07-24 US11452725B2 (en) | 2015-07-21 | 2020-08-20 | Chiral diaryl macrocycles and uses thereof |
US17/819,858 Pending US20230346786A1 (en) | 2015-07-21 | 2022-08-15 | Chiral diaryl macrocycles and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (3) | US20180325901A1 (de) |
EP (2) | EP3325488B1 (de) |
JP (1) | JP6817287B2 (de) |
KR (1) | KR20180033194A (de) |
CN (1) | CN108026109B (de) |
AU (1) | AU2016296878B2 (de) |
BR (1) | BR112018001065A2 (de) |
CA (1) | CA2992324A1 (de) |
DK (1) | DK3325488T3 (de) |
ES (1) | ES2818528T3 (de) |
HK (1) | HK1254606A1 (de) |
IL (1) | IL256868B (de) |
MX (1) | MX2018000718A (de) |
RU (2) | RU2728579C2 (de) |
WO (1) | WO2017015367A1 (de) |
ZA (1) | ZA201800416B (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10618912B2 (en) | 2014-01-24 | 2020-04-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
US10745416B2 (en) | 2017-12-19 | 2020-08-18 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
US11008337B2 (en) | 2015-07-02 | 2021-05-18 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
WO2021108672A1 (en) * | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11155563B2 (en) | 2017-07-28 | 2021-10-26 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
US11291667B2 (en) | 2017-01-25 | 2022-04-05 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11452725B2 (en) | 2015-07-21 | 2022-09-27 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
US11731956B2 (en) | 2018-10-22 | 2023-08-22 | Alumis Inc. | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors |
US11981684B2 (en) | 2022-02-22 | 2024-05-14 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113354653A (zh) * | 2015-07-06 | 2021-09-07 | 特普医药公司 | 二芳基大环多晶型物及其制备方法 |
CN107267458B (zh) * | 2017-07-06 | 2019-10-29 | 中南大学湘雅二医院 | 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用 |
CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
TW201927790A (zh) | 2017-11-10 | 2019-07-16 | 美商安捷克斯製藥公司 | 作為trk激酶抑制劑之巨環化合物及其用途 |
JP2021519297A (ja) * | 2018-03-28 | 2021-08-10 | フォチョン・ファーマシューティカルズ・リミテッドFochon Pharmaceuticals, Ltd. | Trkキナーゼ阻害剤としての大環状化合物 |
JP7092405B2 (ja) * | 2018-04-16 | 2022-06-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジ(ヘテロ)アリール大環状化合物 |
WO2019210835A1 (zh) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
JP2022537385A (ja) * | 2019-06-19 | 2022-08-25 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 大環状キナーゼ阻害剤の多形 |
CN111689883B (zh) * | 2020-05-22 | 2022-02-11 | 上海应用技术大学 | 一种二芳基砜类化合物的合成方法 |
EP4163283A1 (de) * | 2020-06-04 | 2023-04-12 | Scinnohub Pharmaceutical Co., Ltd | Verbindung mit makrocyclischer struktur und verwendung davon |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT690843E (pt) | 1993-03-25 | 2001-01-31 | Upjohn Co | Derivados de indolo substituidos com formilo ou ciano possuindo actividade dopaminergica |
CN1050844C (zh) * | 1993-12-07 | 2000-03-29 | 伊莱利利公司 | 蛋白激酶c抑制剂 |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
ATE301661T1 (de) * | 2000-12-08 | 2005-08-15 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
EP2065380A1 (de) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs |
CA2735420C (en) * | 2008-09-08 | 2016-06-28 | Merck Patent Gmbh | Macrocyclic pyrimidines as protein kinase inhibitors |
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
DK3106463T6 (da) | 2008-10-22 | 2020-02-24 | Array Biopharma Inc | Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
HUE035337T2 (en) * | 2010-05-20 | 2018-05-02 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
EP2508607A1 (de) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medikament zur Leberregeneration und zur Behandlung von Leberversagen |
WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
KR20140059236A (ko) * | 2011-08-19 | 2014-05-15 | 머크 샤프 앤드 돔 코포레이션 | Hcv 프로테아제 억제제의 결정 형태 |
WO2013045653A1 (en) | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
BR112014022106B1 (pt) | 2012-03-06 | 2022-08-02 | Pfizer Inc | Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças |
CA2866164C (en) | 2012-03-09 | 2020-07-07 | Lexicon Pharmaceuticals, Inc. | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
EA031863B1 (ru) * | 2014-01-24 | 2019-03-29 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
CN107735399B (zh) | 2015-07-02 | 2021-01-26 | 特普医药公司 | 作为蛋白质激酶的调节剂的手性二芳基大环 |
CN113354653A (zh) * | 2015-07-06 | 2021-09-07 | 特普医药公司 | 二芳基大环多晶型物及其制备方法 |
BR112018001065A2 (pt) | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | macrociclos diarila quirais e usos dos mesmos |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
KR102645316B1 (ko) | 2017-07-28 | 2024-03-07 | 터닝 포인트 테라퓨틱스, 인크. | 거대환형 화합물 및 이의 용도 |
-
2016
- 2016-07-20 BR BR112018001065-0A patent/BR112018001065A2/pt not_active Application Discontinuation
- 2016-07-20 RU RU2018106245A patent/RU2728579C2/ru active
- 2016-07-20 WO PCT/US2016/043132 patent/WO2017015367A1/en active Application Filing
- 2016-07-20 EP EP16828471.9A patent/EP3325488B1/de active Active
- 2016-07-20 RU RU2020123800A patent/RU2020123800A/ru unknown
- 2016-07-20 CN CN201680052319.6A patent/CN108026109B/zh active Active
- 2016-07-20 KR KR1020187002289A patent/KR20180033194A/ko not_active Application Discontinuation
- 2016-07-20 DK DK16828471.9T patent/DK3325488T3/da active
- 2016-07-20 ES ES16828471T patent/ES2818528T3/es active Active
- 2016-07-20 US US15/745,915 patent/US20180325901A1/en not_active Abandoned
- 2016-07-20 MX MX2018000718A patent/MX2018000718A/es unknown
- 2016-07-20 JP JP2018502668A patent/JP6817287B2/ja active Active
- 2016-07-20 CA CA2992324A patent/CA2992324A1/en active Pending
- 2016-07-20 EP EP20181616.2A patent/EP3733187A1/de active Pending
- 2016-07-20 AU AU2016296878A patent/AU2016296878B2/en active Active
-
2018
- 2018-01-11 IL IL256868A patent/IL256868B/en active IP Right Grant
- 2018-01-19 ZA ZA2018/00416A patent/ZA201800416B/en unknown
- 2018-10-23 HK HK18113572.9A patent/HK1254606A1/zh unknown
-
2020
- 2020-08-20 US US16/998,763 patent/US11452725B2/en active Active
-
2022
- 2022-08-15 US US17/819,858 patent/US20230346786A1/en active Pending
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10618912B2 (en) | 2014-01-24 | 2020-04-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
US11008337B2 (en) | 2015-07-02 | 2021-05-18 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
US11452725B2 (en) | 2015-07-21 | 2022-09-27 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
US11291667B2 (en) | 2017-01-25 | 2022-04-05 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11155563B2 (en) | 2017-07-28 | 2021-10-26 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
US10745416B2 (en) | 2017-12-19 | 2020-08-18 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
US11286265B2 (en) | 2017-12-19 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
US11731956B2 (en) | 2018-10-22 | 2023-08-22 | Alumis Inc. | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors |
WO2021108672A1 (en) * | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11666574B2 (en) | 2019-11-27 | 2023-06-06 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11981684B2 (en) | 2022-02-22 | 2024-05-14 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20180033194A (ko) | 2018-04-02 |
DK3325488T3 (da) | 2020-09-14 |
RU2018106245A3 (de) | 2019-12-26 |
IL256868A (en) | 2018-03-29 |
US20230346786A1 (en) | 2023-11-02 |
JP6817287B2 (ja) | 2021-01-20 |
BR112018001065A2 (pt) | 2018-09-11 |
US11452725B2 (en) | 2022-09-27 |
ES2818528T3 (es) | 2021-04-13 |
CA2992324A1 (en) | 2017-01-26 |
EP3325488B1 (de) | 2020-06-24 |
CN108026109A (zh) | 2018-05-11 |
HK1254606A1 (zh) | 2019-07-26 |
EP3733187A1 (de) | 2020-11-04 |
CN108026109B (zh) | 2021-03-02 |
MX2018000718A (es) | 2020-01-20 |
RU2020123800A (ru) | 2020-10-02 |
IL256868B (en) | 2021-03-25 |
JP2018524382A (ja) | 2018-08-30 |
AU2016296878B2 (en) | 2020-12-17 |
EP3325488A1 (de) | 2018-05-30 |
RU2728579C2 (ru) | 2020-07-30 |
ZA201800416B (en) | 2021-07-28 |
WO2017015367A1 (en) | 2017-01-26 |
RU2018106245A (ru) | 2019-08-21 |
AU2016296878A1 (en) | 2018-01-25 |
EP3325488A4 (de) | 2019-04-24 |
US20210030756A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11452725B2 (en) | Chiral diaryl macrocycles and uses thereof | |
US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US20210214373A1 (en) | Macrocyclic compounds and uses thereof | |
JP2016528288A (ja) | 上昇したc反応性タンパク質レベルを有する固形腫瘍の患者における延命効果 | |
KR20140043314A (ko) | 이중 오로라 키나제/mek 억제제를 사용한 항암 치료법 | |
CA3163095A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
WO2021113339A1 (en) | Macrocycles for use in treating disease | |
CN108473472B (zh) | 作为p70s6激酶抑制剂的2-氨基喹唑啉衍生物 | |
EP3364971B1 (de) | Heterocyclische pdk1-inhibitoren zur verwendung zur behandlung von krebs | |
CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
CA3174455A1 (en) | Therapeutic uses of macrocyclic compounds | |
US11981684B2 (en) | Macrocyclic compounds and uses thereof | |
US20230158034A1 (en) | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors | |
RU2784853C2 (ru) | Комбинационная терапия с применением диарильных макроциклических соединений | |
CN117561255A (zh) | 作为mek抑制剂的3,4-二氢-2,7-萘啶-1,6(2h,7h)-二酮化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: TURNING POINT THERAPEUTICS, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:TP THERAPEUTICS, INC.;REEL/FRAME:050084/0756 Effective date: 20181126 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |